Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viridian Therapeutics (VRDN – Research Report), Fortrea Holdings Inc. (FTRE – Research Report) and Cytokinetics (CYTK – Research Report).
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Viridian Therapeutics (VRDN)
In a report released today, Laura Chico from Wedbush maintained a Buy rating on Viridian Therapeutics, with a price target of $47.00. The company’s shares closed last Friday at $31.92.
According to TipRanks.com, Chico is a 5-star analyst with an average return of
Viridian Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $40.87, implying a 29.1% upside from current levels. In a report issued on December 12, Truist Financial also maintained a Buy rating on the stock with a $41.00 price target.
See today’s best-performing stocks on TipRanks >>
Fortrea Holdings Inc. (FTRE)
Truist Financial analyst Jailendra Singh maintained a Hold rating on Fortrea Holdings Inc. today. The company’s shares closed last Friday at $17.74.
According to TipRanks.com, Singh has 0 stars on 0-5 stars ranking scale with an average return of
Fortrea Holdings Inc. has an analyst consensus of Hold, with a price target consensus of $13.00, a -21.7% downside from current levels. In a report issued on December 15, Barclays also upgraded the stock to Hold with a $15.00 price target.
Cytokinetics (CYTK)
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Cytokinetics. The company’s shares closed last Friday at $62.72.
According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of
Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $88.15, representing a 40.1% upside. In a report issued on December 18, Goldman Sachs also upgraded the stock to Buy with a $95.00 price target.
